https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
Diabetes Drugs Market Future Outlook with
AI-Based Treatment Personalization
The diabetes drugs market focuses on medications used to manage blood glucose levels in patients with
type 1 and type 2 diabetes. This includes insulin therapies, oral hypoglycemics (such as metformin,
sulfonylureas, SGLT-2 and DPP-4 inhibitors), and GLP-1 receptor agonists. With rising global diabetes
prevalence, enhanced screening programs, and a growing emphasis on chronic disease management,
demand for effective, safe, and affordable drug therapies continues to increase. Advances in drug
formulations—like once-weekly injections and oral dosing options—along with improvements in patient
access and adherence, are driving market growth worldwide.
According to Fortune Business Insights, the global diabetes drugs market was valued at USD 88.32 billion in
2024. The market is projected to grow from USD 101.48 billion in 2025 to USD 233.84 billion by 2032,
exhibiting a CAGR of 12.7% during the forecast period. In 2024, North America dominated the diabetes
drugs market with a market share of 49.95%.
Top Companies Leading the Charge
Novo Nordisk A/S (Denmark)
Sanofi (France)
Merck & Co., Inc. (U.S.)
Eli Lilly and Company (U.S.)
AstraZeneca (U.K.)
Novartis AG (Switzerland)
Johnson & Johnson Services, Inc. (U.S.)
Bayer AG (Germany)
Novo Nordisk, Eli Lilly, and Sanofi dominate, collectively controlling over half of the global market share.
Key Industry Development: July 2024
In July 2024, Novo Nordisk received a Complete Response Letter (CRL) from the U.S. FDA regarding its
Biologics License Application for once-weekly basal insulin icodec—a significant setback . While not an
approval, it underscores the company’s effort to expand groundbreaking treatment options.
Market Drivers & Restraints
Drivers:
Growing Diabetes Prevalence: Diabetes is spreading globally, especially type 2, driving demand.
Awareness & Diagnosis: Improved screening and awareness enable earlier interventions.
Product Innovation: Advances in drug classes, delivery systems, and oral therapies fuel adoption.
Emerging Therapies: Ongoing development in gene therapy and nanomedicine is expanding
treatment landscapes.
Restraints:
High Drug Prices: New biologics and branded drugs carry high costs, limiting access in
lower-income regions.
Regulatory & IP Barriers: Complex approval processes and exclusivity rights hinder entry of
generics and biosimilars.
Market Report Coverage
The Fortune Business Insights report offers extensive analysis across segments including drug class,
diabetes type, administration route, distribution channel, and region. It highlights market drivers,
competitive intensity, pricing dynamics, and regulatory trends.
Competitive Landscape
The diabetes sector is intensely competitive. Novo Nordisk continues leading with GLP-1 therapies like
Ozempic and Wegovy. Eli Lilly and Sanofi retain strong positions via insulin and other antidiabetic products.
Merck, AstraZeneca, Novartis, and Bayer are also investing strategically in innovation and expansion.
Segment Insights
By Drug Class
GLP-1 Receptor Agonists: Fastest-growing and market-leading segment, driven by popular
therapies that combine glycemic control and weight loss.
Insulins (Basal, Rapid-Acting, Premixed)
DPP-4 Inhibitors
SGLT2 Inhibitors
https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
Other Classes (e.g., Meglitinides)
By Diabetes Type
Type 2 Diabetes: Dominates demand due to adult obesity and lifestyle patterns.
Type 1 Diabetes: Requires intensive insulin therapy and remains a significant segment.
By Route of Administration
Subcutaneous: Premier route for insulin and GLP-1 agents.
Oral: Increasingly important with the introduction of drugs like Rybelsus (oral semaglutide).
Intravenous: Limited use in hospital settings.
By Distribution Channel
Retail Pharmacies: Most popular channel due to convenience.
Hospital Pharmacies
Online Pharmacies: Gaining importance through telehealth and mail-order models.
Regional Insights
North America
Largest regional market, valued at ~USD 44.12 billion in 2024 (approx. 49.95% share). Growth fueled by
high diabetes rates, insurance coverage, and advanced healthcare infrastructure
Europe
Second largest due to strong healthcare systems and widespread adoption of novel therapies.
Asia-Pacific
Fastest-growing, driven by expanding middle class, rising diabetes prevalence, and enhanced market access
in nations like China and India.
Explore the full research report with detailed insights and
TOC:https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-
100570
Future Market Scope
The diabetes drugs market is set for sustained expansion. Continued innovation in GLP-1 therapies, growth
of oral formulations, and entry of biosimilars will reshape the market. Additionally, emerging treatment
options like gene therapy and nanomedicines promise richer pipelines and options for patients.
Conclusion
In summary, robust market growth is expected in the diabetes drugs sector, fueled by major pharmaceutical
leaders, technological breakthroughs, and rising global disease burden. Anticipated to nearly triple from
2024 to 2032, this sector presents compelling opportunities for innovation-driven companies. Key success
factors include affordability, regulatory agility, and pioneering next-gen therapies.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all
sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them
address unique challenges. Our goal is to empower clients with holistic market intelligence and offer
granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve
sustainable growth. Our experienced analysts and consultants use leading research methodologies to
provide comprehensive market assessments enriched with relevant data.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and
recommendations that help them navigate technological and market changes. Our consulting services are
designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com